Management of patients coinfected with HCV and HIV: A close look at the role for direct-acting antivirals

Gastroenterology

Volumn 142, Issue 6, 2012, Pages

  Naggie, Susanna ^a,b   Sulkowski, Mark S ^c  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug Interaction; HCV; HIV; Liver Disease; Treatment

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; ATAZANAVIR; BOCEPREVIR; CYCLOPHILIN INHIBITOR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; FOSAMPRENAVIR; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; LOPINAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RALTEGRAVIR; RECOMBINANT HEPATITIS B VACCINE; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELAPREVIR; TENOFOVIR;

ANEMIA; ANOREXIA; CAUSE OF DEATH; CHOLELITHIASIS; CLINICAL DECISION MAKING; DEPRESSION; DIZZINESS; DRUG INDUCED HEADACHE; DYSGEUSIA; EDUCATION; FEVER; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; JAUNDICE; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; MALE HOMOSEXUAL; MIXED INFECTION; MORBIDITY; MORTALITY; NAUSEA; NEUTROPENIA; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RASH; REVIEW; SCREENING; THERAPY EFFECT; TREATMENT RESPONSE; VIRUS TRANSMISSION; VOMITING;

EID: 84860306889     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2012.02.012     Document Type: Article

References (90)

1. D. Lavanchy The global burden of hepatitis C Liver Int 29 Suppl 1 2009 74 81
2. K.E. Sherman, S.D. Rouster, R.T. Chung Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group Clin Infect Dis 34 2002 831 837
3. R. Weber, C. Sabin, N. Friis-Møller Liver-related deaths in persons infected with the HIV: the D:A:D study Arch Intern Med 166 2006 1632 1641
4. T. Tencer, H.S. Friedman, J. Li-McLeod Medical costs and resource utilization for hemophilia patients with and without HIV and HCV infection J Manage Care Pharm 13 2007 790 798
5. Naggie S, Park L, Gellad Z, et al. Healthcare utilization and mortality associated with chronic HIV and HCV: more to the story than chronic infection. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 to March 2, 2011; Boston, MA. Abstract 915.
6. R.T. Chung, J. Anderson, P. Volberding Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459
7. F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
8. S.H. Mehta, B.L. Genberg, J. Astemborski Limited uptake of hepatitis C treatment among injection drug users J Community Health 33 2008 126 133
9. Telaprevir [prescribing information] www.incivek.com Accessed November 6, 2011
10. Boceprevir [prescribing information] www.victrelis.com Accessed November 6, 2011
11. J.D. Scott, D.R. Gretch Molecular diagnostics of hepatitis C virus infection: a systematic review JAMA 297 2007 724 732
12. T. Poynard, P. Bedossa, P. Opolon OBSVIRC, METAVIR, CLINIVIR and DOSVIRC Groups Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832
13. J. Massard, V. Ratziu, D. Thabut Natural history and predictors of disease severity in chronic hepatitis C J Hepatol 44 2006 S19 S24
14. S.C. Darby, D.W. Ewart, P.L. Giangrande Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C UK Haemophilia Centre Directors' Organization Lancet 350 1997 1425 1431
15. C. Graham, L. Baden, E. Yu Influence of HIV infection on the course of hepatitis C virus infection: a meta-analysis Clin Infect Dis 33 2001 562 569
16. D. Joshi, J. O'Grady, D. Dieterich Increasing burden of liver disease in patients with HIV infection Lancet 377 2011 1198 1209
17. W. Lin, E.M. Weinberg, A.W. Tai HIV increases HCV replication in a TGF-beta1-dependent manner Gastroenterology 134 2008 803 811
18. A. Balagopal, F.H. Philp, J. Astemborski Human immunodeficiency virus-related microbial translocation and progression of hepatitis C Gastroenterology 135 2008 226 233
19. B. Soto, A. Sanchez-Quijano, L. Rodrigo Human Immunodeficiency virus infection modifies the natural history of chronic parenterraly-acquired hepatitis C with an unusually rapid progression to cirrhosis J Hepatol 26 1997 1 5
20. P. Tebas Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options J Acquir Immune Defic Syndr 49 2008 S86 S92
21. M. Bonacini Alcohol use among patients with HIV infection Ann Hepatol 10 2011 502 507
22. A.A. Chaudhry, M.S. Sulkowski, G. Chander Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort HIV Med 10 2009 133 142
23. N. Qurishi, C. Kreuzberg, G. Lchters Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection Lancet 362 2003 1708 1713
24. J.A. Pineda, J.A. Garcia-Garcia, M. Aguilar-Guisado Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy Hepatology 46 2007 622 630
25. H. Thein, Q. Yi, G.J. Dore Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis AIDS 22 2008 1979 1991
26. Centers for Disease Control and Prevention Viral hepatitis statistics & surveillance www.cdc.gov/hepatitis/Statistics/index.htm Accessed October 5, 2011
27. M. Leruez-Ville, J.M. Kunstmann, M. De Almeida Detection of hepatitis C virus in the semen of infected men Lancet 356 2000 42 43
28. M. Manavir, T. Watkins-Riedel, E. Kucera Evidence of hepatitis C virus in cervical smears J Infect 38 1999 60 61
29. C. Vandelli, F. Renzo, L. Romano Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study Am J Gastroenterol 99 2004 855 859
30. B. Marincovich, J. Castilla, J. del Romero Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples Sex Transm Infect 79 2003 160 162
31. M. Alary, J.R. Joly, J. Vincelette Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men Am J Public Health 95 2005 502 505
32. L. Salleras, M. Bruguera, J. Vidal Importance of sexual transmission of hepatitis C virus in seropositive pregnant women: a case-control study J Med Virol 52 1997 164 167
33. J.G. Feldman, H. Minkoff, S. Landesman Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner-city women Sex Transm Dis 27 2000 338 342
34. D.L. Thomas, J.M. Zenilman, H.J. Alter Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore-an analysis of 309 sex partnerships J Infect Dis 171 1995 768 775
35. R.C. Hershow, L.A. Kalish, B. Sha Hepatitis C virus infection in Chicago women with or at risk for HIV infection: evidence for sexual transmission Sex Transm Dis 25 1998 527 532
36. T. Frederick, P. Burian, N. Terrault Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS) AIDS Patient Care STDS 23 2009 915 923
37. T. Van de Laar, O. Pybus, S. Bruisen Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men Gastroenterology 136 2009 1609 1617
38. J.J. Van der helm, M. Prins, J. del Amo The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007 AIDS 25 2011 1083 1091
39. A.T. Urbanus, T.J. van de Laar, I.G. Stolte Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic AIDS 23 2009 F1 F7
40. M. Danta, D. Brown, S. Bhagani Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours AIDS 21 2007 983 991
41. D.S. Fierer, S.H. Factor, A.J. Uriel Sexual transmission of hepatitis C virus among HIV-infected men who have sex with men - New York City, 2005-1010 MMWR 60 2011 945 950
42. R.A. Tohme, S.D. Holmberg Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 52 2010 1497 1505
43. L.E. Taylor, A.K. DeLong, M.A. Maynard Acute hepatitis C virus in an HIV clinic: a screening strategy, risk factors, and perception of risk AIDS Patient Care STDS 25 2011 571 577
44. T.E. Wiley, M. McCarthy, L. Breidi Impact of alcohol on the histological and clinical progression of hepatitis C infection Hepatology 28 1998 805 809
45. C. Chakvetadze, F. Bani-Sadr, C. Le Pendeven Serologic response to hepatitis B vaccination in HIV-infected patients with isolated positivity for antibodies to hepatitis B core antigen Clin Infect Dis 50 2010 1184 1186
46. O. Launay, D. van der Vliet, A.R. Rosenberg Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial JAMA 305 2011 1432 1440
47. K. Cardell, B. Akerlind, M. Sallberg Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine J Infect Dis 198 2008 299 304
48. S.D. Zucker, X. Qin, S.D. Rouster Mechanism of indinavir-induced hyperbilirubinemia Proc Natl Acad Sci U S A 98 2001 12671 12676
49. L. Morris, A. Distenfeld, E. Amorosi Autoimmune thrombocytopenic purpura in homosexual men Ann Intern Med 96 1982 714 717
50. K.M. Marks, R.M. Clarke, J.B. Bussel Risk factors for thrombocytopenia in HIV-infected patients in the era of potent antiretroviral therapy J Acquir Immune Defic Syndr 52 2009 595 599
51. A. Subramanian, M. Sulkowski, B. Barin MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates Gastroenterology 138 2010 159 164
52. R.K. Sterling, E. Lissen, N. Clumeck Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV co-infection Hepatology 43 2006 1317 1325
53. R.P. Myers, Y. Benhamou, F. Imbert-Bismut Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients AIDS 17 2003 721 725
54. T.B. Kelleher, S.H. Mehta, K. Bhaskar Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index J Hepatol 43 2005 78 84
55. G.D. Kirk, J. Astemborski, S.H. Mehta Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection Clin Infect Dis 48 2009 963 972
56. F. Poordad, J. McCone, B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
57. I.M. Jacobson, J.G. McHutchison, G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus Infection N Engl J Med 364 2011 2405 2416
58. J. Berenguer, J. Alvarez-Pellicer, P.M. Martin Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus Hepatology 50 2009 407 413
59. Sulkowski M, Mehta S, Sutcliffe C, et al. Baseline liver disease is independently associated with risk of death among 631 HIV/HCV co-infected adults with histologic staging. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; February 16-19, 2010; San Francisco, CA. Abstract 166.
60. F.J. Torriani, M. Rodriguez-Torres, J.K. Rockstroh Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients N Engl J Med 351 2004 438 450
61. R.T. Chung, J. Andersen, P. Volberding Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons N Engl J Med 351 2004 451 459
62. Rodriguez-Torres M, Slim J, Bhatti L, et al. Standard versus high dose ribavirin in combination with peginterferon alfa-2a (40KD) in genotype 1 (G1) HCV patients coinfected with HIV: final results of the PARADIGM Study. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30 to November 3, 2009; Boston, MA. Abstract 1561.
63. F. Carrat, F. Bani-Sadr, S. Pol Pegylated interferon alfa-2b vs standard inteferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients JAMA 292 2004 2839 2848
64. M. Nunez, C. Miralles, M.A. Berdun Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO Trial AIDS Res Human Retrovirus 23 2007 972 982
65. M. Laguno, J. Murillas, J.L. Blanco Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients AIDS 18 2004 F27 F36
66. M. Laguno, C. Cifuentes, J. Murillas Randomized trial comparing pegylated interferon alfa-2b versus pegylated interferon alfa-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients Hepatology 49 2009 22 31
67. N.I. Rallon, S. Naggie, J.M. Benito Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatic C virus-coinfected patients AIDS 24 2010 F23 F29
68. S.H. Mehta, G.M. Lucas, L.B. Mirel Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic AIDS 20 2006 2361 2369
69. B.R. Bacon, S.C. Gordon, E. Lawitz Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
70. S. Zeuzem, P. Andreone, S. Pol Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
71. Bruno S, Vierling JM, Esteban R, et al. Boceprevir in addition to standard of care enhanced SVR in hepatitis C virus (HCV) genotype-1 with advanced fibrosis/cirrhosis: subgroup analysis of SPRINT-2 and RESPOND-2 studies. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 7.
72. Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virologic response in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 12.
73. Marcellin P, Jacobson IM, Zeuzem S, et al. Telaprevir in combination with peginterferon alfa-2a and ribavirin: analysis of predefined subpopulations in the phase 3 ADVANCE trial. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 451.
74. Zeuzem S, Andreone P, Pol S, et al. REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ ribavirin. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 5.
75. Dieterich DT, Soriano V, Sherman KE, et al. Telaprevir in combination with peginterferon alfa-2a/ribavirin in HCV/HIV co-infected patients: SVR12 interim analysis. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2011; Seattle, WA. Abstract 46.
76. Sulkowski M, Pol S, Cooper C, et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2011; Seattle, WA. Abstract 47.
77. Van Heeswijk R, Vandevoorde A, Boogaerts G, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 to March 2, 2011; Boston, MA. Abstract 119.
78. Van Heeswijk R, Gard V, Boogaerts, et al. The pharmacokinetic interaction between telaprevir and raltegravir in healthy volunteers. Presented at: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2011; Chicago, IL. Abstract A1-1738a.
79. Kasserra C, Hughes E, Treitel M, et al. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions. Presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 to March 2, 2011; Boston, MA. Abstract 118.
80. Hulskotte E, Feng HP, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and darunavir. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2011; Seattle, WA. Abstract 771LB.
81. de Kanter CTMM, Blonk MI, Colbers APH, et al. Pharmacokinetic of the HIV integrase inhibitor raltegravir. Presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2011; Seattle, WA. Abstract 772LB.
82. D.L. Thomas, J.G. Bartlett, M.G. Peters Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons Clin Infect Dis 2011 Dec 14 [Epub ahead of print]
83. J.M. Miro, M. Laguno, A. Moreno Hospital Clinic OLT in HIV Working Group Management of end stage liver disease (ESLD): what is the current role of orthotopic liver transplantation (OLT)? J Hepatol 44 2006 S140 S145
84. M.V. Ragni, S.H. Belle, K. Im Survival of human immunodeficiency virus-infected liver transplant recipients J Infect Dis 188 2003 1412 1420
85. Terrault NA, Barin B, Schiano T, et al. Survival and risk of severe HCV recurrence in liver transplant recipients co-infected with HIV and HCV. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases; October 30 to November 1, 2009; Boston, MA. Abstract 195.
86. Soriano V, Sherman KE, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. AIDS 201;25:2197-2208.
87. J. Schlutter New drugs hit the target Nature 474 2011 S5 S7
88. E.J. Gane, S.K. Robers, C.A.M. Stedman Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomized, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
89. Zeuzem S, Buggisch P, Agarwal K, et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PegIFN/RBV for up to 28 days in treatment nave, genotype 1 HCV subjects. Presented at: 61st Annual Meeting of the American Association for the Study of Liver Diseases; October 29 to November 2, 2010; Boston, MA. Abstract LB-1.
90. Lok A, Gardiner D, Lawitz E, et al. Quadruple therapy with BMS-790052, BMS-650032 and peg-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders. Presented at: 46th Annual Meeting of the European Association for the Study of Liver Diseases; March 30 to April 3, 2011; Berlin, Germany. Abstract 418.